ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A ... end-stage renal disease, or death. Secondary outcomes included changes ...

Endothelin (ET) is a recently discovered 21-amino acid peptide that has potent physiologic and pathophysiologic effects that appear to be involved in the development of heart failure. These ...

AZ’s ZENITH-CKD study looked at the combination of its SGLT2 drug dapagliflozin with zibotentan, an endothelin A (ETA ... with an increased risk of kidney function loss over time, so a key ...